Cantargia AB: Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer

STOCKHOLM, June 9, 2022 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM CET), focusing

Related Keywords

Stockholm ,Sweden ,Belgium ,Gasthuisberg ,Region Flamande ,Madrid ,Spain ,California ,United States ,Leuven ,Poland ,Warsaw ,L67 ,Belgian ,Los Angeles ,Sudheer Doss ,Prnewswire Cantargia ,Luniversidad Complutense ,Luis Paz ,Eric Van Cutsem ,Van Cutsem ,University Of California ,Belgian Foundation ,University Of Warsaw ,Oncology Department ,University Hospitals Gasthuisberg ,National Oncology Research Center ,Pancreatic Cancer Action Network Pan ,Nasdaq Stockholm ,Prof Eric Van Cutsem ,Prof Van Cutsem ,Chief Business Officer ,Pancreatic Cancer Action Network ,Division Head ,Digestive Oncology ,Medical University ,Belgian Royal Academy ,Luis Paz Ares ,Medical Oncology Department ,Hospital Universitario ,Associate Professor ,Lung Cancer Unit ,Cantargia ,Most ,Adunolimab ,Ombinational ,Synergy ,Pancreatic ,Dancer ,Mall ,Fell ,Young ,